Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study-Reference-Cited by-同舟云学术

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study

Published:2021-03-01 Issue: Volume: Page:
ISSN:1424-3997
Container-title:Swiss Medical Weekly
language:en
Short-container-title:Swiss Med Wkly

Author:

Stoffel Sandro Tiziano¹,von Moos Roger²,Thrlimann Beat³,Cathomas Richard⁴,Gillessen Silke²,Zrrer-Hrdi Ursina⁵,von Briel Thomas⁶,Anchisi Sandro⁷,Feller Anita⁸,Schr Corinne⁹,Dietrich Daniel⁹,Schwenkglenks Matthias¹⁰,Lupatsch Judith E¹,Mark Michael Thomas²

Affiliation:

1. Institute of Pharmaceutical Medicine, University of Basel, Switzerland / Swiss Group for Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland

2. Department of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland

3. Kantonsspital St. Gallen, Switzerland

4. Kantonsspital Graubünden | Department of Hematology/Oncology, Kantonsspital Graubünden

5. Kantonsspital Winterthur, Switzerland

6. Klinik Hirslanden, Zurich, Switzerland

7. Hôpital du Valais, Sion, Switzerland

8. Foundation National Institute for Cancer Epidemiology and Registration (NICER), c/o University of Zurich, Switzerland / National Agency for Cancer Registration (NACR) operated by NICER, c/o University of Zurich, Switzerland

9. Swiss Group for Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland

10. Institute of Pharmaceutical Medicine, University of Basel, Switzerland

Publisher

EMH Swiss Medical Publishers, Ltd.

Subject

General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer;JCO Oncology Practice;2024-03

2. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects;Supportive Care in Cancer;2024-03

3. Authors’ reply to Laurent;BMJ;2023-12-04

4. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study;BMJ;2023-10-25

5. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2022-07-07